Skip to main content

Elsevier Secures Publishing Rights for Premium Titles for 2023

--News Direct--

Elsevier, a leading scientific publisher, and global information analytics business specializing in science and health, announced today that it will be the new publisher of six influential society journals starting in January 2023:

  • American Journal of Clinical Nutrition
  • The Journal of Nutrition
  • Journal of Thrombosis and Haemostasis
  • American Journal of Transplantation
  • Laboratory Investigation
  • Modern Pathology

The newly acquired titles represent the following societies and add to Elsevier’s expansive global health publishing portfolio:

  • American Society for Nutrition (ASN)
  • United States and Canadian Academy of Pathology (USCAP)
  • International Society on Thrombosis and Haemostasis (ISTH)
  • The American Society of Transplant Surgeons (ASTS)
  • American Society of Transplantation (AST)

All are considered internationally renowned sources of knowledge and impactful study in the fields of pathology, nutrition, transplantation, haematology and peripheral vascular disease.

It is an honor to partner with five established societies that have trusted Elsevier as the official publisher of their important journals. True to our commitment to supporting research and clinical practice, we are dedicated to placing our full range of industry-leading resources for authors, editors, reviewers and readers, in the disposal of our latest additions. With our continuous support and seamless collaboration these six valued titles can harness the benefits of a reliable global publishing partner allowing them to maximize their contribution to scientific research and clinical practice in their respective fields” said Carl Schwarz Senior Vice President, Health and Medical Sciences, at Elsevier.

Elsevier will officially welcome the journals into their portfolio beginning in January 2023. They will be part of Elsevier’s title-by-title subscription model instead of a collection.

Learn more about these exceptional titles or contact us for more information.

About Elsevier

As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders.

Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Contact Details

Elsevier

Dan DiPietro-James, Global Media Relations Director

+1 773-251-8744

dan.james@elsevier.com

Company Website

https://www.elsevier.com/

View source version on newsdirect.com: https://newsdirect.com/news/elsevier-secures-publishing-rights-for-premium-titles-for-2023-510154664

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.